Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Papillomavirus Infections 1Neoplasms 1Hematologic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Human Papillomavirus Recombinant Vaccine nonavalent × 90 days × Clear all
NCT03023631 2026-05-20

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 4 Active not recruiting
48 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04206813 2026-04-29

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

Boston Medical Center

Phase 4 Active not recruiting
352 enrolled

Papillomavirus Infections

NCT06658405 2026-03-18

HPV2

Centre Oscar Lambret

Phase 2 Recruiting
85 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡